Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
- PMID: 36283738
- PMCID: PMC9608645
- DOI: 10.1136/jitc-2021-004022corr1
Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Erratum for
-
CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy.J Immunother Cancer. 2022 May;10(5):e004022. doi: 10.1136/jitc-2021-004022. J Immunother Cancer. 2022. PMID: 35580929 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials